WO2009064476A1 - Preparation of sitagliptin intermediate - Google Patents
Preparation of sitagliptin intermediate Download PDFInfo
- Publication number
- WO2009064476A1 WO2009064476A1 PCT/US2008/012813 US2008012813W WO2009064476A1 WO 2009064476 A1 WO2009064476 A1 WO 2009064476A1 US 2008012813 W US2008012813 W US 2008012813W WO 2009064476 A1 WO2009064476 A1 WO 2009064476A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trifluorophenyl
- process according
- alkyl ester
- amino
- acid
- Prior art date
Links
- XAKRGTQXCNOINF-YFHOEESVSA-N CC(C)(C)OC(N/C(/Cc(c(F)c1)cc(F)c1F)=C\C(OC)=O)=O Chemical compound CC(C)(C)OC(N/C(/Cc(c(F)c1)cc(F)c1F)=C\C(OC)=O)=O XAKRGTQXCNOINF-YFHOEESVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the invention encompasses a process for the preparation of a Sitagliptin intermediate.
- Sitagliptin, (3i?)-3-amino-l-[9-(trifluoromethyl)-l,4,7,8- tetrazabicyclo[4.3.0]nona-6,8-dien-4-yl]-4-(2,4,5- trifluorophenyl)butan-l-one, has the following chemical structure:
- Sitagliptin is currently marketed in its phosphate salt in the United States under the tradename JANUVIATM in its monohydrate form. JANUVIATM is indicated to improve glycemic control in patients with type 2 diabetes mellitus.
- Sitagliptin phosphate is a glucagon-like peptide 1 metabolism modulator, hypoglycemic agent, and dipeptidyl peptidase IV inhibitor. Sitagliptin phosphate is described in PCT Publication No. WO 2005/003135.
- Sitagliptin can be obtained by condensation of 2 key intermediates. The first intermediate is (3R)-amino-4-(2,4,5-trifluorophenyl)butanoic acid ("Synthon I"). Synthon I has the following formula:
- PCT Publication No. WO 2004/085378 refers to the synthesis of Sitagliptin intermediate (3R)-[protected-amino]-4-(2,4,5-trifiuorophenyl)butanoic acid via stereoselective hydrogenation of a prochiral enamine, 3-Amino-l-(3-trifluoromethyl-5,6- dihydro-8H-[l,2,4]triazolo[4,3-a]purazin-7-yl)-4-(2,4,5-trifluorophenyl)but-2-en-l-one, using Rhodium complex with (R,S)-tert-butyl-Josipos ligand.
- PCT Publication No. WO 2004/087650 refers to the synthesis of Sitagliptin intermediate (3R)-[protected-amino]-4- (2,4,5-trifluorophenyl)butanoic acid via chiral reduction of 3-Oxo-4-(2,4,5- trifluorophenyl)-butyric acid with Ru-(S)-BINAP complex, followed by inversion of stereochemical center, achieved by Mitsunobu cyclization of (3S)-N-Benzoyloxy-3- hydroxy-4-(2,4,5-trifluorophenyl)butyramide.
- U.S. Patent No. 6,699,871 refers to the synthesis of the Sitagliptin intermediate (3R)-[protected-amino]-4-(2,4,5-trifluorophenyl)butanoic acid by using diazomethane, which is a very dangerous and explosive reagent, and can not be used in industrial scale. Additionally, (S)-2,5-dihydro-2-isopropyl-3,6-dimethoxypyrazine is used as the starting material and leads to high costs.
- the present invention provides intermediate compounds in the synthesis of Sitagliptin: 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, and amino protected-3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, and the stereoselective reduction of these compound to give Synthon I, or the amino-protected Synthon I, which are key intermediates in the preparation of Sitagliptin.
- alkyl refers to C 1 -C 6 hydrocarbons.
- the Ci-C 6 hydrocarbon is methyl or ethyl.
- the term optically pure refers to a sample of an optically active compound, comprising at least 90% percent of the predominant enantiomer.
- room temperature refers to a temperature of about 20°C to about 35°C, more preferably about 25 0 C to about 35°C, more preferably about 25°C to about 30 0 C, and most preferably about 25°C.
- the present invention encompasses a process for the preparation of a Sitagliptin key intermediate, 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester via enamine reduction. This synthesis gives high stereoselectivity. [0015] In one embodiment, the present invention encompasses a process for preparing 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester ("Synthon I"-alkyl ester), comprising reducing 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester of the following formula:
- R is C 1 -C 6 alkyl (such as methyl, ethyl, iso-propyl and tert-butyl), C 6 -Ci 2 sryh C 7 - Ci 2 arylalkyl, or C 7 -Ci 2 alkylaryl, in the presence of hydrogen source and a chiral catalyst to obtain Synthon I-alkyl ester.
- the reduction is stereoselective.
- the reduction reaction is carried out in the presence of an organic solvent. An acid may also be added to the reaction mixture.
- the process for preparing 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester comprises combining 3-amino-4-(2,4,5-trifiuorophenyl) but-2- enoic acid alkyl ester with a chiral catalyst, and a hydrogen source, and optionally an acid, and in the presence of a solvent such as CpC 6 alcohol, or a C 1 -C 6 fluorinated alkylalcohol.
- the molar ratio of the 3-amino-4-(2,4,5-trifluorophenyl) but-2-enoic acid alkyl ester and the chiral catalyst is from about 0.001% to about 5%.
- 3-amino-4-(2,4,5-trifiuorophenyl)but-2-enoic acid alkyl ester used in the above process can be prepared using any method known in the art, for example, according to the reaction disclosed in Tetrahedron: Asymmetry 17 (2006), 205-209, and depicted in the following scheme:
- the chiral catalyst is a complex Ru-BINAP.
- the complex is formed from a mixture of a first metal complex and a chiral ligand.
- the complexes are [Ru(COD)Cb] n - preferably X is F, Cl, or Br, more preferably X is Cl or Br, and most preferably, X is Cl.
- the chiral ligand is (R or S)- 2,2'-bis(diphenylphosphino)-l,l'- binaphthyl (BINAP), or derivatives thereof. More preferably, the ligand is (R)-2,2 - bis(diphenylphosphino)- 1 , 1 '-binaphthyl or (S)-2,2'-bis(diphenylphosphino)- 1,1'- binaphthyl, and most preferably. Most preferably, the ligand is (R)-2,2'- bis(diphenylphosphino)-l,l'-binaphthyl.
- the solvent for the reaction is selected from the group consisting of Ci-C 6 alcohols, and C]-C 6 fluorinated alkyl alcohols; more preferably, the solvent is a C 1 - C 6 alcohol, or a Cj-C 6 fluorinated alkyl alcohol selected from the group consisting of: methanol, ethanol, isopropyl alcohol, and trifluoroethanol; preferably, ethanol or trifiuoroethanol.
- the acid is an organic acid. More preferably, the organic acid is selected from the group consisting of: acetic acid, chloroacetic acid, propionic acid, and methanesulfonic acid. Most preferably, the organic acid is acetic acid. However, where the alcohol is a fluorinated Ci-C 6 alkyl alcohol, such as trifluoroethanol, no acid is needed.
- the reaction is carried out at about 5 to 7 bar of hydrogen pressure. More preferably, the pressure is about 5.5 to 6.5 bar.
- the reaction mixture is maintained at a temperature of greater than 50°C to about 140°C, preferably about 60 0 C to about 100°C (e.g.
- the reaction mixture may be maintained at a temperature of about 80°C.
- the reaction mixture is preferably maintained at this temperature for about 10 to 80 hours, preferably about 15 hours to about 60 hours, and more preferably about 15 hours to about 45 hours. Good results and high yields have been obtained maintaining the reaction fixture for a period of about 24 to about 45 hours.
- the reaction mixture is preferably maintained at a temperature of about 60 0 C to about 100°C (e.g. about 60 0 C to 80°C), and most preferably about 80 0 C.
- the mixture is maintained at this temperature for a period of about 10 to about 25 hours (e.g., about 10 to about 15 hours), more preferably.12 to about 24 hours, and most preferably about 15-18 hours.
- the 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester (“Synthon I"- alkyl ester) can be purified and recovered using any method known to those skilled in the art, for example, by extracting, washing, drying and evaporating.
- the obtained 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester (“Synthon F'-alkyl ester) is optically pure.
- the ratio between the two enantiomers is preferably about 60% to about 100%, more preferably about 80% to about 100%, more preferably about 90% to about 100%, most preferably about 95% to about 99.8% (for example, the ration is 95.4:4.6 to about 99.5:0.5).
- the predominant enantiomer is the (3R) enantiomer of Synthon I-alkyl ester.
- the chemical purity of 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester according to HPLC is more that about 90%, preferably about 90% to about 100%, and most preferably about 90% to about 94% (preferably about 91.1 % to 93.14 %) .
- this process for preparing 3-amino-4-(2,4,5- trifluorophenyl)butanoic acid, alkyl ester comprises combining 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, a chiral organic acid, a reducing reagent and an organic solvent, and maintaining the reaction mixture for a sufficient period of time to obtain 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester.
- the mixture is maintained for about 4 to about 24 hours.
- the molar ratio of 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, organic acid, and reducing reagent is from about 0.25 to about 0.4.
- about 5 to about 40 ml of organic solvent is used per gram of 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester.
- the organic acid is optically pure.
- the organic acid is (R or S)-mandelic acid.
- the reducing reagent is a borohydride or hydride reducing reagent selected from the group consisting of sodium borohydride, sodium cyanoborohydride, lithium borohydride, and lithium aluminum hydride. More preferably, the reducing reagent is sodium borohydride.
- the organic solvent is an ether, such as a C 4 to C 8 alkyl ether or a C 4 to C 8 cyclic ether. Most preferably the organic solvent is tetrahydrofuran.
- the mixture is stirred at a temperature of about -5 0 C to about 30 0 C, more preferably at about room temperature, i.e., about 25°C for about 8 to about 24 hours.
- the mixture is The mixture is stirred at this temperature range preferably for a period of about 30 minutes to about 20 hours, more preferably about 30 minutes to about 12 hours. More preferably the mixture is stirred at this temperature range for a period of about 1 to about 12 hours, and most preferably for about 12 hours.
- the obtained 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester may be recovered and purified using any method known in the art, for example, by filtration.
- the obtained 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester is optically pure.
- the predominant enantiomer is the (3R) enantiomer of Synthon I-alkyl ester.
- the enantiomers ratio of the obtained 3-amino-4-(2,4,5- trifluorophenyl)butanoic acid, alkyl ester is 92.2:7.8.
- the present invention encompasses a process for preparing Sitagliptin or salts thereof, comprising obtaining 3-amino-4-(2,4,5- trifluorophenyl)butanoic acid, alkyl ester by any of the methods described above, and further converting it to Sitagliptin or salts thereof.
- the present invention encompasses 3-amino-protected-
- R' is BOC.
- the present invention encompasses a process for preparing 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester comprising converting the carbonyl group of 3-oxo-4-(2,4,5-trifluorophenyl)butanoic acid alkyl ester into a protected enamine functional group, according to the reaction.
- R' is BOC.
- the invention encompasses a process for preparing 3- tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester comprising reacting 3-oxo-4-(2,4,5-trifluorophenyl)butanoic acid alkyl ester with tert butyl carbamate.
- the reaction is carried out in the presence of a catalytic amount (0.01-0.1 equivalents) of organic acid.
- the reaction is carried out in the presence of an organic solvent.
- the process for preparing 3-tert-butoxycarbonylamino-4- (2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester comprises combining tert-butyl carbamate with 3-oxo-4-(2,4,5-trifluorophenyl)butanoic acid alkyl ester, a catalytic amount (0.06 equivalents) of organic acid and an organic solvent (8 ml/gr).
- the molar ratio of tert-butyl carbamate, 3-oxo-4-(2,4,5-trifluorophenyl)butanoic acid alkyl ester, and organic acid is from about 10 to about 100.
- the organic solvent is used in an amount of from about 5 to about 20 ml per gram of 3-oxo-4-(2,4,5- trifluorophenyl)butanoic acid alkyl ester.
- Tert-butyl carbamate used in the above process can be prepared using any method known in the art, for examples according to the procedure disclosed in Tetrahedron: Asymmetry, 12 (2001), 2989 and in Organic Synthesis, 48 (1968), 32.
- the organic acid is selected from the group consisting of p- toluenesulfonic acid, methansulfonic acid, and trifluoroacetic acid. More preferably, the organic acid is p-toluenesulfonic acid.
- the organic solvent is a C 6 -Cj 2 aromatic solvent, such as benzene, toluene, or chlorobenzene, or a halogenated Ci-C 6 alkane, such as methylene chloride; preferably the solvent is methylene chloride.
- water removal is carried out during the reaction.
- water removal may be carried out by the addition of a drying agent, or by azeotropic distillation.
- a drying agent is introduced to the reaction mixture.
- the drying agent may be selected from any drying agent known to the skilled in the art.
- the drying agent is a molecular sieve, more preferably, MS-4A (Molecular Sieves-4A).
- the water may be removed from the reaction mixture by azeotropic distillation.
- 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester is further recovered and purified by any method known in the art, for example, by evaporation and purification using HPLC techniques and/or crystallization.
- the present invention encompasses a process for preparing Sitagliptin or salts thereof, comprising obtaining 3-tert-butoxycarbonylamino-4- (2,4,5-trifluorophenyl) but-2-enoic acid alkyl ester as described above, and further converting it to Sitagliptin or salts thereof.
- the present invention encompasses a process for preparing the amino-protected group, 3-amino-protected-4-(2,4,5-trifluorophenyl) butanoic acid alkyl ester comprising reducing 3-amino-protected-4-(2,4,5-trifluorophenyl) but-2-enoic acid alkyl ester, in the presence of hydrogen and a chiral catalyst.
- the reduction is stereoselective.
- the reduction is carried out by a process as defined in any embodiment of the present invention.
- the reaction is conducted in the presence of a solvent such as Ci-C 6 alcohol or a fluorinated Ci -6 alkyl alcohol.
- Preferred metal complexes, chiral ligands, solvents and conditions are as described in any of the above embodiments for the reduction of 3-amino-4-(2,4,5-trifluorophenyl) but-2-enoic acid alkyl ester.
- the process for preparing the amino-protected group "Synthon I", 3-tert- butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butanoic acid alkyl ester comprises combining 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester with a chiral catalyst, a hydrogen source and a Ci-C 6 alcohol.
- the molar ratio of 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, a metal complex, and a chiral ligand is from about 5% to about 0.01%.
- about 3 ml to about 10 ml of the Ci-C 6 alcohol is used per gram of 3-tert-butoxycarbonylamino-4- (2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester.
- the chiral catalyst is a complex Ru-BINAP.
- the complex is formed from a mixture of a first metal complex and a chiral ligand.
- the chiral ligand is (R or S)- 2,2'-bis(diphenylphosphino)- 1,1 '-binaphthyl or (R or S)- 2,2'-bis(diphenylphosphino)-l,l'-binaphthyl.
- the ligand is (R)-2,2'- bis(diphenylphosphino)- 1 , 1 '-binaphthyl or (S)-2,2'-bis(diphenylphosphino)- 1,1'- binaphthyl.
- the ligand is (R)-2,2'-bis(diphenylphosphino)- 1,1 '-binaphthyl.
- the solvent is a Ci-C 6 alcohol or a fluorinated Ci-C 6 alcohol, and is more preferably a Ci-C 4 alcohol or a fluorinated Ci-C 4 alcohol, and is most preferably selected from the group consisting of: methanol, ethanol, isopropyl alcohol, and trifluoroethanol. More preferably, the alcohol is trifluoroethanol.
- the reaction is carried out in the presence of an organic acid.
- the organic acid is selected from the group consisting of: acetic acid, chloroacetic acid, propionic acid, and methanesulfonic acid.
- the organic acid is acetic acid.
- the reaction is carried out at a hydrogen pressure of about 3 bar to about 8 bar, more preferably about 4 bar to about 7 bar, and most preferably about 5 to 7 bar, particularly at about 5 bar.
- the reaction mixture is maintained at about 40 0 C to about 100 0 C, more preferably about 60 0 C to about 100 0 C, and most preferably about 60 0 C to about 80 0 C for about 10 to 80 hours, preferably about 20 hours to about 60 hours, and more preferably about 30 hours, to about 50 hours.
- the reaction is carried out at about 5 bar at 80 0 C for about 40 hours.
- the protected 3-arnino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester can be purified and recovered using any method known to the skilled in the art, for example, by extracting, washing, drying and evaporating.
- the obtained protected-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid, alkyl ester is optically pure.
- the predominant enantiomer is the (3R) enantiomer of protected-Synthon I-alkyl ester.
- the present invention encompasses a process for preparing Sitagliptin or salts thereof, comprising obtaining 3-tert-butoxycarbonylamino-4- (2,4,5-trifluorophenyl)butanoic acid alkyl ester by any of the methods described above, and further converting it to Sitagliptin or salts thereof.
- Sitagliptin can be prepared by other processes, such as coupling 3-protected- amino-4-(2,4,5-trifluorophenyl)butanoic acid with 3-(trifluoromethyl)-5,6,7,8- tetrahydro[l,2,4]triazolo[4,3- ⁇ ]pyrazine hydrochloride to obtain (R)-3-protected-amino-l- (3-(trifluoromethyl)-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5- trifluorophenyl)butan-l-one; and then removing the amino protected group to obtain Sitagliptin.
- 4-(3-(trifluoromethyl)-5,6-dihydro-[ 1 ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)-l-(2,4,5-trifluorophenyl)-4-oxobutan-2-yl-carbamate is optically pure.
- the obtained coupling product is (R)-4-(3-(trifluoromethyl)-5,6-dihydro- [l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-l-(2,4,5-trifluorophenyl)-4-oxobutan-2-yl- carbamate.
- the 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butanoic acid is cooled to a temperature of about -10 0 C to about 25°C, more preferably about 0 0 C in the presence of a first organic solvent; followed by the addition of Dicyclohexylcarbodiimide in a second organic solvent; introducing 3-(trifluoromethyl)- 5,6,7,8-tetrahydro[l,2,4]triazolo[4,3- ⁇ ]pyrazine hydrochloride, an organic base, and a catalyst to the reaction mixture; and recovering 4-(3-(trifluoromethyl)-5,6-dihydro- [l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-l-(2,4,5-trifluorophenyl)-4-oxobutan-2-yl- carbamate.
- the first and the second organic solvents are selected from the group consisting of aprotic solvent, such as dimethylformamide, tetrahydrofuran, and dichloromethane.
- Dimethylformamide is preferred.
- a solution of Dicyclohexylcarbodiimide and Dimethylformamide is added drop-wise.
- the catalyst is 4-Dimethylaminopyridine ("DMAP").
- Suitable organic bases for this reaction are alkyl amines, preferably C 1 -C 6 trialkyl amines, more preferably triethylamine, diisopropyl ethyl amine, and N methyl morpholine.
- the deprotection of the amine protecting group is carried out by introducing a solution of concentrated hydrochloric acid into a solution of tert-butyl-4-(3- (trifluoromethyl)-5,6-dihydro-[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-l-(2,4,5- trifluorophenyl)-4-oxobutan-2-yl-carbamate and an organic solvent selected from a group consisting OfC 1 -Co alcohols, most preferably, the organic solvent is iso-propanol; heating the reaction mixture at about 40 0 C for a sufficient period of time.
- the reaction mixture is heated at about 25°C to about reflux, preferably to about 40 0 C for about 1 hour to about 24 hours, preferably an hour to about 5 hours, and more preferably about 2 hours; basifying the reaction mixture with an inorganic base, such as alkali bicarbonate, alkali carbonates, or alkali hydroxides, for example, sodium hydroxide; and recovering Sitagliptin.
- an inorganic base such as alkali bicarbonate, alkali carbonates, or alkali hydroxides, for example, sodium hydroxide
- Sitagliptin may be recovered from the reaction mixture using any known method, such as evaporation, extraction, and filtration.
- Solvent A Acetonitril
- Solvent B 10 mM KH2PO4 (1.36 g) and 10 niM (0.4 g) NaOH in
- the reaction was stirred for 2 hours, then, 65 mL of DCC solution was added drop-wise, and after another 1 hour of stirring in an ice bath, the last 65 mL of DCC solution was added drop- wise.
- the reaction was stirred at room temperature over night.
- the mixture was filtrated by vacuum filtration and washed with DMF 2X50 mL.
- the solvent was evaporated and EtOAc was added (1400 mL), the organic phase washed with 90 mL of 5% citric acid, 60 mL of 10% citric acid, and 100 mL of saturated NaHCO 3 , dried over Na 2 SO 4 and evaporated to yield a beige solid.
- the product was dissolved in IPA (300 mL) by heating to reflux.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US303307P | 2007-11-13 | 2007-11-13 | |
US61/003,033 | 2007-11-13 | ||
US355307P | 2007-11-16 | 2007-11-16 | |
US61/003,553 | 2007-11-16 | ||
US6865308P | 2008-03-06 | 2008-03-06 | |
US61/068,653 | 2008-03-06 | ||
US7285408P | 2008-04-02 | 2008-04-02 | |
US61/072,854 | 2008-04-02 | ||
US13084308P | 2008-06-03 | 2008-06-03 | |
US61/130,843 | 2008-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009064476A1 true WO2009064476A1 (en) | 2009-05-22 |
Family
ID=40404514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/012813 WO2009064476A1 (en) | 2007-11-13 | 2008-11-13 | Preparation of sitagliptin intermediate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009064476A1 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010131025A1 (en) * | 2009-05-11 | 2010-11-18 | Generics [Uk] Limited | Sitagliptin synthesis |
WO2011127794A1 (en) * | 2010-04-12 | 2011-10-20 | 上海源力生物技术有限公司 | Chiral cyclic beta-amino aryl butyric acid derivatives, their preparation methods and methods for preparation of chiral beta-amino aryl butyric acid derivatives via them |
EP2392575A1 (en) | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
WO2011151443A1 (en) | 2010-06-04 | 2011-12-08 | Lek Pharmaceuticals D.D. | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS |
EP2397141A1 (en) | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
EP2423178A1 (en) * | 2010-07-28 | 2012-02-29 | Chemo Ibérica, S.A. | Process for the production of sitagliptin |
CN102391142A (en) * | 2011-09-30 | 2012-03-28 | 山东铂源化学有限公司 | Method for recycling 3-(S)-amino-4-(2,4,5-trifluoro-phenyl)-butyrate |
CN102485718A (en) * | 2010-12-03 | 2012-06-06 | 浙江海翔药业股份有限公司 | Sitagliptin intermediate and its preparation method |
US8278486B2 (en) | 2008-12-31 | 2012-10-02 | Chiral Quest, Inc. | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives |
EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
EP2527320A1 (en) | 2011-05-27 | 2012-11-28 | LEK Pharmaceuticals d.d. | Preparation of Sitagliptin Intermediates |
CN102838603A (en) * | 2011-06-24 | 2012-12-26 | 上海医药工业研究院 | Preparation method of intermediate compound of sitagliptin |
WO2013013833A1 (en) | 2011-07-27 | 2013-01-31 | Farma Grs, D.O.O. | Process for the preparation of sitagliptin and its pharmaceutically acceptable salts |
CN103172539A (en) * | 2011-12-23 | 2013-06-26 | 上海阳帆医药科技有限公司 | Preparation method of new diabetes drug sitagliptin intermediate aminobenzene butyric acid derivative |
EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
CN103232455A (en) * | 2013-05-14 | 2013-08-07 | 聊城九州和谷生物科技有限公司 | Industrial production method of sitagliptin |
WO2013128000A1 (en) | 2012-03-02 | 2013-09-06 | Moehs Iberica S.L. | Novel crystalline form of sitagliptin sulfate |
EP2674432A1 (en) | 2012-06-14 | 2013-12-18 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds |
WO2014023930A1 (en) | 2012-08-08 | 2014-02-13 | Cipla Limited | Process for the preparation of sitagliptin and intermediate compounds |
TWI453182B (en) * | 2009-06-26 | 2014-09-21 | Jiangsu Hengrui Medicine Co | Process for the preparation of (r)-β-amino-phenyl butyric acid derivatives |
CN104447374A (en) * | 2013-09-17 | 2015-03-25 | 深圳翰宇药业股份有限公司 | Preparation method of sitagliptin and intermediate thereof |
WO2015145333A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of sitagliptin and its intermediate |
CN105061434A (en) * | 2015-07-30 | 2015-11-18 | 新发药业有限公司 | Low-cost preparation method of sitagliptin phosphate |
WO2015189862A1 (en) * | 2014-06-10 | 2015-12-17 | Council Of Scientific & Industrial Research | Chiral amines, a process for preparation and use thereof |
CN105315286A (en) * | 2014-07-30 | 2016-02-10 | 连云港润众制药有限公司 | Preparation of Sitagliptin |
KR20160146124A (en) | 2015-06-11 | 2016-12-21 | 동방에프티엘(주) | Improved method of sitagliptin |
KR20160148371A (en) | 2015-06-16 | 2016-12-26 | 경동제약 주식회사 | Novel intermediates for preparing DPP-IV inhibitors, preparing method thereof and preparing method of DPP-IV inhibitors using the same |
CN106458853A (en) * | 2014-10-11 | 2017-02-22 | 浙江华海药业股份有限公司 | Method for preparing sitagliptin intermediate via asymmetrical reduction method |
CN109928888A (en) * | 2017-12-19 | 2019-06-25 | 浙江瑞博制药有限公司 | A kind of preparation method of sitagliptin intermediate |
KR20210057603A (en) | 2019-11-12 | 2021-05-21 | 제이투에이치바이오텍 (주) | Process for preparing sitagliptin |
CN113121540A (en) * | 2020-01-15 | 2021-07-16 | 鲁南制药集团股份有限公司 | Synthesis method of sitagliptin free alkali |
WO2021227641A1 (en) | 2020-05-11 | 2021-11-18 | 浙江医药股份有限公司新昌制药厂 | METHOD FOR PREPARING CHIRAL 4-ARYL-β-AMINO ACID DERIVATIVE |
CN114644568A (en) * | 2020-12-21 | 2022-06-21 | 浙江医药股份有限公司新昌制药厂 | Purification method of sitagliptin intermediate |
US11459549B2 (en) | 2018-05-10 | 2022-10-04 | China Fortune Way Company | Method for biocatalytic synthesis of Sitagliptin and intermediate thereof |
KR20220145631A (en) | 2021-04-22 | 2022-10-31 | 주식회사 메디켐코리아 | Improved manufacturing method of sitagliptin phosphate salt |
CN116891838A (en) * | 2023-09-11 | 2023-10-17 | 瑞博(苏州)制药有限公司 | Alkene reductase mutant, composition, biological material and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087650A2 (en) * | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors |
-
2008
- 2008-11-13 WO PCT/US2008/012813 patent/WO2009064476A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087650A2 (en) * | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors |
Non-Patent Citations (2)
Title |
---|
AHN ET AL: "Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 9, 3 April 2007 (2007-04-03), pages 2622 - 2628, XP022015357, ISSN: 0960-894X * |
KUBRYK M ET AL: "Application of the asymmetric hydrogenation of enamines to the preparation of a beta-amino acid pharmacophore", TETRAHEDRON ASYMMETRY, PERGAMON, OXFORD; GB, vol. 17, no. 2, 23 January 2006 (2006-01-23), pages 205 - 209, XP024962542, ISSN: 0957-4166, [retrieved on 20060123] * |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278486B2 (en) | 2008-12-31 | 2012-10-02 | Chiral Quest, Inc. | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives |
AU2010247193B2 (en) * | 2009-05-11 | 2016-05-19 | Generics [Uk] Limited | Sitagliptin synthesis |
CN102574856B (en) * | 2009-05-11 | 2016-09-21 | 基因里克斯(英国)有限公司 | The synthesis of sitagliptin |
US8846916B2 (en) | 2009-05-11 | 2014-09-30 | Generics [Uk] Limited | Sitagliptin synthesis |
WO2010131025A1 (en) * | 2009-05-11 | 2010-11-18 | Generics [Uk] Limited | Sitagliptin synthesis |
CN102574856A (en) * | 2009-05-11 | 2012-07-11 | 基因里克斯(英国)有限公司 | Sitagliptin synthesis |
TWI453182B (en) * | 2009-06-26 | 2014-09-21 | Jiangsu Hengrui Medicine Co | Process for the preparation of (r)-β-amino-phenyl butyric acid derivatives |
WO2011127794A1 (en) * | 2010-04-12 | 2011-10-20 | 上海源力生物技术有限公司 | Chiral cyclic beta-amino aryl butyric acid derivatives, their preparation methods and methods for preparation of chiral beta-amino aryl butyric acid derivatives via them |
CN102471294A (en) * | 2010-04-12 | 2012-05-23 | 上海源力生物技术有限公司 | Chiral cyclic beta-amino aryl butyric acid derivatives, their preparation methods and methods for preparation of chiral beta-amino aryl butyric acid derivatives via them |
EP2392575A1 (en) | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
WO2011151443A1 (en) | 2010-06-04 | 2011-12-08 | Lek Pharmaceuticals D.D. | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS |
EP2397141A1 (en) | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
EP2423178A1 (en) * | 2010-07-28 | 2012-02-29 | Chemo Ibérica, S.A. | Process for the production of sitagliptin |
WO2012072036A1 (en) * | 2010-12-03 | 2012-06-07 | 浙江海翔药业股份有限公司 | Intermediates of sitagliptin and preparation process thereof |
CN102485718A (en) * | 2010-12-03 | 2012-06-06 | 浙江海翔药业股份有限公司 | Sitagliptin intermediate and its preparation method |
WO2012136383A2 (en) | 2011-04-08 | 2012-10-11 | Lek Pharmaceuticals D.D. | Preparation of sitagliptin intermediates |
EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
US9174930B2 (en) | 2011-04-08 | 2015-11-03 | Lek Pharmaceuticals D.D. | Preparation of sitagliptin intermediates |
EP2527320A1 (en) | 2011-05-27 | 2012-11-28 | LEK Pharmaceuticals d.d. | Preparation of Sitagliptin Intermediates |
WO2012163815A1 (en) | 2011-05-27 | 2012-12-06 | Lek Pharmaceuticals D.D. | Preparation of sitagliptin intermediates |
CN102838603B (en) * | 2011-06-24 | 2015-05-13 | 上海医药工业研究院 | Preparation method of intermediate compound of sitagliptin |
CN102838603A (en) * | 2011-06-24 | 2012-12-26 | 上海医药工业研究院 | Preparation method of intermediate compound of sitagliptin |
WO2013013833A1 (en) | 2011-07-27 | 2013-01-31 | Farma Grs, D.O.O. | Process for the preparation of sitagliptin and its pharmaceutically acceptable salts |
CN102391142A (en) * | 2011-09-30 | 2012-03-28 | 山东铂源化学有限公司 | Method for recycling 3-(S)-amino-4-(2,4,5-trifluoro-phenyl)-butyrate |
CN103172539A (en) * | 2011-12-23 | 2013-06-26 | 上海阳帆医药科技有限公司 | Preparation method of new diabetes drug sitagliptin intermediate aminobenzene butyric acid derivative |
CN103172539B (en) * | 2011-12-23 | 2016-08-03 | 上海阳帆医药科技有限公司 | The preparation method of Glucovance sitagliptin intermediate aminobenzene butyric acid derivative |
WO2013104774A1 (en) | 2012-01-12 | 2013-07-18 | Lek Pharmaceuticals D.D. | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF |
EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
US9181260B2 (en) | 2012-03-02 | 2015-11-10 | Moehs Iberica, S.L. | Crystalline form of sitagliptin sulfate |
WO2013128000A1 (en) | 2012-03-02 | 2013-09-06 | Moehs Iberica S.L. | Novel crystalline form of sitagliptin sulfate |
US9388188B2 (en) | 2012-06-14 | 2016-07-12 | Lek Pharmaceuticals D.D. | Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compounds |
WO2013186326A1 (en) | 2012-06-14 | 2013-12-19 | Lek Pharmaceuticals D.D. | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ß-AMINOBUTYRYL SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,4]DIAZOLO[4,3-alpha]PYRAZIN-7-YL COMPOUNDS |
EP2674432A1 (en) | 2012-06-14 | 2013-12-18 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds |
WO2014023930A1 (en) | 2012-08-08 | 2014-02-13 | Cipla Limited | Process for the preparation of sitagliptin and intermediate compounds |
US9233967B2 (en) | 2012-08-08 | 2016-01-12 | Cipla Limited | Process for the preparation of sitagliptin and intermediate compounds |
CN103232455A (en) * | 2013-05-14 | 2013-08-07 | 聊城九州和谷生物科技有限公司 | Industrial production method of sitagliptin |
CN104447374A (en) * | 2013-09-17 | 2015-03-25 | 深圳翰宇药业股份有限公司 | Preparation method of sitagliptin and intermediate thereof |
CN104447374B (en) * | 2013-09-17 | 2016-08-17 | 深圳翰宇药业股份有限公司 | A kind of sitagliptin and the preparation method of intermediate thereof |
WO2015145333A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of sitagliptin and its intermediate |
WO2015189862A1 (en) * | 2014-06-10 | 2015-12-17 | Council Of Scientific & Industrial Research | Chiral amines, a process for preparation and use thereof |
CN105315286A (en) * | 2014-07-30 | 2016-02-10 | 连云港润众制药有限公司 | Preparation of Sitagliptin |
CN106458853B (en) * | 2014-10-11 | 2020-03-27 | 浙江华海药业股份有限公司 | Method for preparing sitagliptin intermediate by asymmetric reduction method |
CN106458853A (en) * | 2014-10-11 | 2017-02-22 | 浙江华海药业股份有限公司 | Method for preparing sitagliptin intermediate via asymmetrical reduction method |
EP3156391A4 (en) * | 2014-10-11 | 2018-01-17 | Zhejiang Huahai Pharmaceutical Co., Ltd | Method for preparing sitagliptin intermediate via asymmetrical reduction method |
US10189760B2 (en) | 2014-10-11 | 2019-01-29 | Zhejiang Huahai Pharmaceutical Co., Ltd. | Method for preparing sitagliptin intermediate via asymmetrical reduction method |
KR20160146124A (en) | 2015-06-11 | 2016-12-21 | 동방에프티엘(주) | Improved method of sitagliptin |
KR101772898B1 (en) | 2015-06-11 | 2017-08-31 | 동방에프티엘(주) | Improved method of sitagliptin |
KR20160148371A (en) | 2015-06-16 | 2016-12-26 | 경동제약 주식회사 | Novel intermediates for preparing DPP-IV inhibitors, preparing method thereof and preparing method of DPP-IV inhibitors using the same |
CN105061434A (en) * | 2015-07-30 | 2015-11-18 | 新发药业有限公司 | Low-cost preparation method of sitagliptin phosphate |
CN109928888A (en) * | 2017-12-19 | 2019-06-25 | 浙江瑞博制药有限公司 | A kind of preparation method of sitagliptin intermediate |
US11459549B2 (en) | 2018-05-10 | 2022-10-04 | China Fortune Way Company | Method for biocatalytic synthesis of Sitagliptin and intermediate thereof |
KR20210057603A (en) | 2019-11-12 | 2021-05-21 | 제이투에이치바이오텍 (주) | Process for preparing sitagliptin |
CN113121540A (en) * | 2020-01-15 | 2021-07-16 | 鲁南制药集团股份有限公司 | Synthesis method of sitagliptin free alkali |
CN113121540B (en) * | 2020-01-15 | 2024-01-26 | 鲁南制药集团股份有限公司 | Synthesis method of sitagliptin free alkali |
WO2021227641A1 (en) | 2020-05-11 | 2021-11-18 | 浙江医药股份有限公司新昌制药厂 | METHOD FOR PREPARING CHIRAL 4-ARYL-β-AMINO ACID DERIVATIVE |
CN114644568A (en) * | 2020-12-21 | 2022-06-21 | 浙江医药股份有限公司新昌制药厂 | Purification method of sitagliptin intermediate |
KR20220145631A (en) | 2021-04-22 | 2022-10-31 | 주식회사 메디켐코리아 | Improved manufacturing method of sitagliptin phosphate salt |
CN116891838A (en) * | 2023-09-11 | 2023-10-17 | 瑞博(苏州)制药有限公司 | Alkene reductase mutant, composition, biological material and application thereof |
CN116891838B (en) * | 2023-09-11 | 2023-11-28 | 瑞博(苏州)制药有限公司 | Alkene reductase mutant, composition, biological material and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009064476A1 (en) | Preparation of sitagliptin intermediate | |
US20090192326A1 (en) | Preparation of sitagliptin intermediate | |
CA2810393C (en) | Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament | |
KR101726468B1 (en) | Process for the preparation of nebivolol | |
KR20060126965A (en) | Process of preparing o-carbamoyl compounds in the presence of active amine group | |
WO2003097632A1 (en) | Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives | |
WO2015037460A1 (en) | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-(BIPHENYL-4-YL)-2-[(t-BUTOXYCARBONYL)AMINO]PROPAN-1-OL | |
RU2715233C2 (en) | Method of producing nitrogen mustard derivatives | |
WO2013114173A1 (en) | A novel process for the preparation of sitagliptin | |
JP5899204B2 (en) | Process for producing chiral β-aminocarboxamide derivative | |
KR101152898B1 (en) | Enhanced preparation method of dipeptidyl peptidase-Ⅳ inhibitor and intermediates thereof | |
JP2016164143A (en) | Processes and intermediates for preparing macrocyclic protease inhibitor of hcv | |
KR100714197B1 (en) | Process for the preparation of voglibose | |
KR100743617B1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
JP3184758B2 (en) | Method for producing optically active 4-hydroxy-2-pyrrolidone | |
US20040030144A1 (en) | Optically active amine derivative and method of synthesis | |
JP3088328B2 (en) | Method for producing optically active 2-phenyl-2- (2'-piperidinyl) acetic acid ester derivative | |
US20210061757A1 (en) | Process for the synthesis of optically active beta-amino alcohols | |
JP2008007457A (en) | POST-TREATMENT METHOD OF beta-HYDROXYCARBONYL COMPOUND | |
EP1926709A1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
US20100168385A1 (en) | Process for preparing enantiomerically enriched amino-alcohols | |
JP4187822B2 (en) | Process for producing optically active 4-hydroxy-2-pyrrolidone | |
KR20160008873A (en) | Novel beta-sulfinamino malonate derivatives and process for preparing the same, and process for preparing sitagliptin using the same | |
JP2003342259A (en) | Method for producing optically active cis-piperidine derivative | |
JP2004099609A (en) | Method for producing optically active 7-amino-5-azaspiro[2.4]heptane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08850792 Country of ref document: EP Kind code of ref document: A1 |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Ref document number: 61/003,553 Country of ref document: US Date of ref document: 20090827 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED Ref document number: 61/068,653 Country of ref document: US Date of ref document: 20090827 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08850792 Country of ref document: EP Kind code of ref document: A1 |